Based on the key measurements obtained from Vor Biopharma's financial statements, Vor Biopharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Vor Biopharma's Other Stockholder Equity is relatively stable compared to the past year. As of 03/14/2025, Property Plant And Equipment Gross is likely to grow to about 70.3 M, while Short and Long Term Debt Total is likely to drop slightly above 25.4 M. Key indicators impacting Vor Biopharma's financial strength include:
The essential information of the day-to-day investment outlook for Vor Biopharma includes many different criteria found on its balance sheet. An individual investor should monitor Vor Biopharma's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Vor Biopharma.
Vor Biopharma competes with Monte Rosa, Design Therapeutics, Erasca, Edgewise Therapeutics, and Adicet Bio. Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell therapies for cancer patients. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Vor Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 135 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Vor Biopharma's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Vor Biopharma's current stock value. Our valuation model uses many indicators to compare Vor Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vor Biopharma competition to find correlations between indicators driving Vor Biopharma's intrinsic value. More Info.
Vor Biopharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Vor Biopharma's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Vor Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Vor Biopharma Systematic Risk
Vor Biopharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Vor Biopharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Vor Biopharma correlated with the market. If Beta is less than 0 Vor Biopharma generally moves in the opposite direction as compared to the market. If Vor Biopharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Vor Biopharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Vor Biopharma is generally in the same direction as the market. If Beta > 1 Vor Biopharma moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Vor Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vor Biopharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Vor Biopharma growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Vor Biopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Vor Biopharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Vor Biopharma based on widely used predictive technical indicators. In general, we focus on analyzing Vor Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Vor Biopharma's daily price indicators and compare them against related drivers.
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.